Sai Life Sciences is a full-service CRO-CDMO that works with innovator pharma and biotech companies globally to accelerate the discovery, development and commercialisation of complex small molecules. Today, it has over 3'000 employees across its R&D and manufacturing sites in India, UK and USA.
Products, services, technology
Sai Life Sciences’ drug discovery services span the journey from target ID and validation to IND through Medicinal Chemistry, Biology, DMPK & Toxicology. Its manufacturing unit delivers cGMP API & intermediates for early phase, late phase and commercial molecules across US, Europe and Japan.
For innovator pharma and biotech companies, spanning start-ups, small & mid-sized pharma, and large pharma companies, we offer both project-based and FTE based models to provide services including integrated drug discovery, process development and scale-up, clinical supplies & cGMP manufacturing.
At Sai Life Sciences, we deliver scientific expertise with a greater purpose. We work with innovator pharma and biotech companies to accelerate the discovery, development and manufacturing of complex small molecules for a healthier tomorrow.
In 2016, we set a vision to support our global innovator partners in bringing 25 new medicines to life by 2025. We crossed this milestone two years ahead of schedule and are poised to sustain this momentum on the back of a strong portfolio of molecules at various stages of clinical development.
Sai Life Sciences has 2,900 employees, of which 1500 are in R&D, 800 in Manufacturing and 300 in Quality. The company has 290+ PhDs and 1691 post graduates.
Through networking and collaboration opportunities with innovator biotech and pharmaceutical companies.
We would like to get in touch with innovator pharma and biotech companies, who are keen to work with partners to accelerate the discovery and development of new drugs.